Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.

by: Iola Bonggay

The United States Food and Drug Administration, otherwise referred to as the USFDA, an agency operating within the United States Department of Health and Human Services that is generally responsible for protecting and promoting public health through the regulation and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, veterinary products, and cosmetics.

The USFA has recently formed a collaboration with the National Institutes of Health to establish the Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.

The primary goal of the program is to develop computational fluid dynamics (CFD) model of orally inhaled drug products that can account for drug product characteristics and physiological parameters on total and regional deposition in the lungs.

This is all in conjunction with the USFDA's objective of developing a CFD model that will be capable of of predicting highly localized deposition of pharmaceutically relevant polydisperse aerosols from metered dose inhalers (MDIs) and dry powder inhalers (DPIs).

In addition, the results that will be derived from this study will then be utilized to create a linked CFD-compartment model that can predict the effects of lung deposition on safety (systemic exposure) and efficacy (local delivery) for locally acting orally inhaled drugs.

  (continued...)

Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
  Page 2

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Excellence in Hemoglobinopathies Research Award Program
The National Institutes of Health has formed a collaboration with the National Heart, Lung, and Blood Institute (NHLBI) in an effort to establish the Excellence in Hemoglobinopathies Research Award Program wherein both agencies have agreed to financially support the creation of studies that could potentially improve high-impact multi-disciplinary basic and translational research studies in the hemoglobinopathies.

---

Genomic Advances to Wound Repair
The National Institutes of Health has coordinated with the National Institute of Nursing Research (NINR) to establish a program called Genomic Advances to Wound Repair in an effort to jump-start research studies that have the potential to deepen the understanding of genomic mechanism associated with the repair and development of wounds that are chronic in nature, which implies that these wounds have failed to enter into a reparative process after three months.

---

International Research Collaboration on Drug Abuse and Addiction
The National Institutes of Health, in collaboration with the National Institute on Drug Abuse (NIDA), has recently established the International Research Collaboration on Drug Abuse and Addiction Program wherein they seek to solicit collaborative research applications regarding addiction and drug use, through the utilization of special opportunities and resources that exist outside the United States of America.

---

Grand Challenges in Global Mental Health: Integrating Mental Health into Chronic Disease Care Provision in Low- and Middle-Income Countries
The National Institutes of Health has recently formed a partnership with the National Institute of Mental Health (NIMH) in order to establish the Grand Challenges in Global Mental Health: Integrating Mental Health into Chronic Disease Care Provision in Low- and Middle-Income Countries Program.

---